ASLNASLAN Pharmaceuticals Ltd

Nasdaq www.aslanpharma.com


$ 0.47 $ 0.00 (0.66 %)    

Tuesday, 30-Apr-2024 15:52:07 EDT
QQQ $ 423.38 $ -8.16 (-1.89 %)
DIA $ 377.96 $ -5.67 (-1.48 %)
SPY $ 501.59 $ -8.08 (-1.58 %)
TLT $ 88.19 $ -0.76 (-0.85 %)
GLD $ 211.99 $ -4.31 (-1.99 %)
$ 0.46
$ 0.48
$ 0.00 x 0
$ 0.00 x 0
$ 0.47 - $ 0.49
$ 0.39 - $ 4.69
245,328
na
56.17M
$ 1.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 aslan-pharmaceuticals-reports-interim-results-from-phase-2-study-of-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients

https://www.sec.gov/Archives/edgar/data/1722926/000095017024046201/asln-ex99_1.htm 

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 hc-wainwright--co-maintains-buy-on-aslan-pharma-lowers-price-target-to-9

HC Wainwright & Co. analyst Yi Chen maintains ASLAN Pharma (NASDAQ:ASLN) with a Buy and lowers the price target from $17...

 piper-sandler-reiterates-overweight-on-aslan-pharma-lowers-price-target-to-10

Piper Sandler analyst Edward Tenthoff reiterates ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fr...

 piper-sandler-maintains-overweight-on-aslan-pharma-lowers-price-target-to-10

Piper Sandler analyst Edward Tenthoff maintains ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fro...

 piper-sandler-maintains-overweight-on-aslan-pharma-maintains-15-price-target

Piper Sandler analyst Edward Tenthoff maintains ASLAN Pharma (NASDAQ:ASLN) with a Overweight and maintains $15 price target.

 aslan-pharmaceuticals-begins-to-enroll-patients-in-us-under-an-updated-protocol-in-the-ongoing-trek-dx-trial

TREK-DX is the first randomized, double-blind, placebo-controlled trial to be conducted in AD patients who have been previously...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION